TABLE OF CONTENTS
Volume 14, Issue 3 (March 2007)
Original Articles
Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma
E Alici, B Björkstrand, A Treschow, A Aints, C I E Smith, G Gahrton and M S Dilber
Cancer Gene Ther 14: 227-232; advance online publication, November 3, 2006; doi:10.1038/sj.cgt.7701006
Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model
H Dzojic, W-S Cheng and M Essand
Cancer Gene Ther 14: 233-240; advance online publication, October 20, 2006; doi:10.1038/sj.cgt.7701007
Adenoviral-mediated interferon 
overcomes resistance to the interferon protein in various cancer types and has marked bystander effects
X Zhang, Z Yang, L Dong, A Papageorgiou, D J McConkey and W F Benedict
Cancer Gene Ther 14: 241-250; advance online publication, November 10, 2006; doi:10.1038/sj.cgt.7701011
A gene transfer comparative study of HSA-conjugated antiangiogenic factors in a transgenic mouse model of metastatic ocular cancer
E Frau, C Magnon, P Opolon, E Connault, D Opolon, F Beerman, M Abitbol, M Perricaudet and C Bouquet
Cancer Gene Ther 14: 251-261; advance online publication, November 3, 2006; doi:10.1038/sj.cgt.7701005
The effects of FasL on inflammation and tumor survival are dependent on its expression levels
A Wada, Y Tada, K Kawamura, Y Takiguchi, K Tatsumi, T Kuriyama, T Takenouchi, J O-Wang and M Tagawa
Cancer Gene Ther 14: 262-267; advance online publication, October 20, 2006; doi:10.1038/sj.cgt.7701008
Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis
M-A Shibata, J Morimoto, H Doi, S Morishima, M Naka and Y Otsuki
Cancer Gene Ther 14: 268-278; advance online publication, November 10, 2006; doi:10.1038/sj.cgt.7701009
Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts
E Kikuchi, S Menendez, C Ozu, M Ohori, C Cordon-Cardo, C R Logg, N Kasahara and B H Bochner
Cancer Gene Ther 14: 279-286; advance online publication, January 12, 2007; doi:10.1038/sj.cgt.7701013
A novel MASH1 enhancer with N-myc and CREB-binding sites is active in neuroblastoma
F Watt, R Watanabe, W Yang, N Ågren, Y Arvidsson and K Funa
Cancer Gene Ther 14: 287-296; advance online publication, November 24, 2006; doi:10.1038/sj.cgt.7701012
Anticancer activity of an adenoviral vector expressing short hairpin RNA against BK virus T-ag
S Sabbioni, E Callegari, R Spizzo, A Veronese, G Altavilla, A Corallini and M Negrini
Cancer Gene Ther 14: 297-305; advance online publication, January 12, 2007; doi:10.1038/sj.cgt.7701014
Efficient transfection of tumors facilitated by long-term therapeutic ultrasound in combination with contrast agent: from in vitro to in vivo setting
M Duvshani-Eshet and M Machluf
Cancer Gene Ther 14: 306-315; advance online publication, January 12, 2007; doi:10.1038/sj.cgt.7701015
Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects
T Wenger, J Mattern, T L Haas, M R Sprick, H Walczak, K-M Debatin, M W Büchler and I Herr
Cancer Gene Ther 14: 316-326; advance online publication, December 22, 2006; doi:10.1038/sj.cgt.7701016
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells
L Kasman, P Lu and C Voelkel-Johnson
Cancer Gene Ther 14: 327-334; advance online publication, December 22, 2006; doi:10.1038/sj.cgt.7701017
